Vivus up on heart drug study

Investor's Business Daily

A study said the biotech's obesity drug Qsymia reduced certain risk factors for heart disease. Patients who took Qsymia for more than a year showed improved blood pressure, cholesterol and triglyceride levels, in addition to significant weight loss. The news sent Vivus' (VVUS) stock up 2.6% to 12.43 .

View Comments (0)